Membranous nephropathy: A review on the pathogenesis, diagnosis, and treatment  by Lai, Wei Ling et al.
Journal of the Formosan Medical Association (2015) 114, 102e111Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.j fma-onl ine.comREVIEW ARTICLEMembranous nephropathy: A review on the
pathogenesis, diagnosis, and treatment
Wei Ling Lai a, Ting Hao Yeh a, Ping Min Chen, Chieh Kai Chan,
Wen Chih Chiang*, Yung Ming Chen, Kwan Dun Wu,
Tun Jun Tsai aDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanReceived 10 March 2014; received in revised form 7 November 2014; accepted 12 November 2014KEYWORDS
membranous
nephropathy;
pathogenesis;
phospholipase A2
receptor antibody;
treatmentConflicts of interest: The authors
* Corresponding author. Department
100, Taiwan.
E-mail address: wcchiang@ntu.edu
a These two authors contributed eq
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0929-6646/Copyright ª 2014, ElsevierIn adults, membranous nephropathy (MN) is a major cause of nephrotic syndrome. However,
the etiology of approximately 75% of MN cases is idiopathic. Secondary causes of MN are auto-
immune diseases, infection, drugs, and malignancy. The pathogenesis of MN involves formation
of immune complex in subepithelial sites, but the definite mechanism is still unknown. There
are three hypotheses about the formation of immune complex, including preformed immune
complex, in situ immune-complex formation, and autoantibody against podocyte membrane
antigen. The formation of immune complex initiates complement activation, which subse-
quently leads to glomerular damage. Recently, the antiphospholipase A2 receptor antibody
was found to be associated with idiopathic MN. This finding may be useful in the diagnosis
and prognosis of MN. The current treatment includes best supportive care, which consists of
the use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, lipid-
lowering agents, and optimal control of blood pressure. Immunosuppressive agents should
be used for patients who suffer from refractory proteinuria or complications associated with
nephrotic syndrome. Existing evidence supports the use of a combination of steroid and alky-
lating agents. This article reviews the epidemiology, pathogenesis, diagnosis, and the
treatment of MN.
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Membranous nephropathy (MN) is a common cause of
nephrotic syndrome in adults.1 Patients with MN usually
present with severe proteinuria, edema, hypoalbuminemia,
and hyperlipidemia. MN is a glomerulopathy with charac-
teristic histopathological features of subepithelial immune-
complex deposit and subsequent thickening of glomerular
basement membrane. The etiology of approximately 75% of
MN cases is idiopathic. During the past decade, several
studies have led to the identification of possible patho-
genesis. Although spontaneous remission occurs in approx-
imately one third of MN patients, 30e40% of the patients
progress toward end-stage renal disease within 5e15 years.
All patients with MN should receive excellent supportive
care. Immunosuppressive agents are central to the treat-
ment of MN. Risk and benefit for prescription should be
individualized, and patient-dependent factors, such as age
and comorbidities, should be considered. The purpose of
this review is to highlight these considerable progresses and
discuss their implications in clinical practice.Epidemiology
The incidence of primary MN is 10 per million populations
per year.2e4 The peak incidence of MN is in the fourth to
fifth decade of life.5 A pooled analysis of studies of patients
with idiopathic MN found a 2:1 predominance of men.6
Approximately 75% of the MN cases occur as an idio-
pathic (primary) disease.7 The remainder, as secondary MN,
is associated with autoimmune diseases (e.g., systemic
lupus erythematosus), infection (e.g., hepatitis B or hepa-
titis C), drugs (e.g., penicillamine, gold), and malignancies
(e.g., colon or lung cancer).
In patients older than the age of 60 years, MN is associated
with malignancy in 20e30% of cases. In a cohort study in
France, the incidence of cancer was significantly higher in
these patients than in the general population (standardized
incidence ratio Z 9.8 for men and 12.3 for women). The
most common malignancies were lung cancer and prostate
cancer. The frequency of malignancy increased with age.1 In
another large cohort study in Norway, the incidence of
cancer was significantly higher in patients with MN than in
the age- and sex-adjusted general population (standardized
incidence ratio, 2.25). Themedian time from diagnosis of MN
to cancer was 60 months. Patients with MN who developed
cancer were older (65 years vs. 52 years, p < 0.001).8
Although spontaneous remission of the nephrotic syndrome
occurs in approximately one third of patients, 30e40% of the
patients progress toward end-stage renal disease within
5e15 years.1Pathogenesis
The formation of immune complex in subepithelial sites is
central to MN. However, the mechanisms of deposit for-
mation remain elusive. Three major putative mechanisms
are proposed so far.
The first hypothesis stresses the passive entrapment of
preformed immune complexes (Fig. 1A). Most protein mightbe forced across the glomerular capillary wall due to higher
intraglomerular pressure and negatively charged capillary
wall. Lupus nephritis is an excellent example of immune-
complexes-related human kidney disease. Preformed im-
mune complexes, containing antibodies to double-stranded
DNA, histone, ribonucleoproteins, and others, are found in
patients with systemic lupus erythematous.9 In addition,
levels of circulating immune complexes were found to
correlate with disease activity.10 Anti-DNA and DNA immune
complexes were detected in glomerular elutes from lupus
patients.11 Therefore, it was proposed that immune-
complex deposits in the glomeruli of lupus patients reflect
entrapment of preformed immune complexes.
The second hypothesis is that the pathogenic circulating
antigens are localized, or planted, in the subepithelial
sites, and these antibodies subsequently form in situ
immune-complex deposits with antibodies (Fig. 1B). The
hepatitis B virus (HBV) was found to be strongly associated
with glomerulonephritis, especially MN. With regard to
pathologic findings in patients with HBV-related glomeru-
lonephritis, HBeAg is found to be distributed along the
glomerular capillary wall. Clusters of viral-like particles
were detected within immune deposits. It is proposed that
the HBV antigen might serve as the circulating antigens,
which are localized in the glomerulus. Further interaction
with antibodies forms immune-complex deposits in HBV-
related glomerulonephritis patients.12e14 In addition, hep-
atitis C virus antigens,15e17 Helicobacter pylori anti-
gens,18,19 tumor antigens,20e24 and thyroid antigens25e28
were found in immune deposits in patients with secondary
MN.
In a small group of children with MN, cationic bovine
serum albumin (BSA) acts, through binding to the anionic
glomerular capillary wall, as an externally planted antigen.
Antibodies then bind to the planted antigen to form the
immune complex [immunoglobulin (Ig)G4 and IgG1]. Cow’s
milk is the major source of BSA, which is processed by the
intestine and modified by intestinal microbiota. In com-
parison with normal individuals, the immature intestinal
wall of these patients may be more permeable to cationic
BSA and allow for the entry of BSA antigen into circulation.
Elimination of BSA from the diet might be beneficial in BSA-
related MN. The titer of circulating BSA and anti-BSA anti-
bodies strongly correlates with the clinical condition and
decreases substantially during remission.29 It is noteworthy
that the in situ mechanism also contributes to pathogenesis
of lupus nephritis. DNA, nucleosomes, histone, and other
antigens can bind to glomeruli, and serve as planted
antigen.30
The third mechanism focuses on the effect of autoanti-
bodies that bind to podocyte membrane antigens, thereby
causing subepithelial deposition of immune complex
(Fig. 1C). The Heymann nephritis model has been exten-
sively studied as a model of MN. It was first described in
1959 and played a vital role in the identification of a culprit
antigen.31 In 1978, Couser et al32 reported the formation of
subepithelial immune complex following the direct perfu-
sion of bloodless kidneys with the pathogenic IgG antibody.
This study established a novel mechanism, in situ immune-
complex formation, in the development of MN.
Several possible culprit antigens were identified in ex-
periments. Kerjaschki and Farquhar in the early 1980s
Figure 1 Three possible immunological mechanisms of membranous nephropathy. (A) Preformed immune complex. The pre-
formed immune complexes are entrapped in subepithelial space. (B) Planted antigens. The circulating pathogenic antigens are
localized, or planted, in the subepithelial sites, which subsequently form in situ immune-complex deposits with antibodies. (C)
Podocyte autoantigen. Autoantibodies bind to podocyte membrane antigens and lead to subepithelial deposition of immune
complex.
104 W.L. Lai et al.identified the podocyte antigen, megalin, in rats.33 Megalin
is a 600-kDa single transmembrane receptor protein that
belongs to the low-density lipoprotein receptor family.
Megalin is responsible for the normal tubular reabsorption,
and is also expressed in human podocytes.34 Epitope-
specific responses are involved in the pathogenesis. In a
previous study in an animal model, a fragment of megalin
can induce autoantibodies against podocyte, therefore
initiate podocyte injury leading to glomerular damage and
proteinuria.35 However, thus far, antimegalin antibodies
were not isolated from a patient with MN.
The neutral endopeptidase was identified in a rare
subset of patients with alloimmune neonatal MN.36 A
neutral endopeptidase-deficient mother may develop an
antibody against neutral endopeptidase during conception
and transmit the antibody during next pregnancy to sub-
sequent fetus. Alloimmunization was due to the truncation
of exon 7 of the MME gene, which encodes neutral endo-
peptidase.37 Screening of the families with the disease is
crucial to subsequent pregnancies.
In 2009, Beck et al38 identified a novel podocyte antigen,
which is mainly an M-type transmembrane phospholipase A2
receptor (PLA2R). Using serum from patients with MN, the
experiment successfully demonstrated a specific antibody
targeting PLA2R. PLA2R and IgG4 are colocalized within
subepithelial deposits. The sensitivity of the anti-PLA2R
test for MN is approximately 70%; the specificity is nearly
100%. The anti-PLA2R antibodies are promising biomarkers
to discriminate between primary and secondary MN.38e41
Patients with other causes of the nephrotic syndrome or
healthy individuals have no detectable anti-PLA2R anti-
body. A very low prevalence of the anti-PLA2R antibody was
observed in secondary forms of MN associated with infec-
tious diseases, drug intoxication, graft-versus-host disease,
or malignancy. There was also a strong correlation of anti-
PLA2R antibodies with disease activities.
42,43 A possible
autoimmune disease nature of the currently classified
idiopathic MN is also elucidated. Other culprit antigens
were also identified in experiments, including a-enolase,44
aldose reductase, and superoxide dismutase 2.45,46
Despite these progresses, the autoimmune basis of MN is
not fully understood. The recent genomewide association
studies using single-nucleotide polymorphism (SNP) tech-
nology identified two significant alleles. Two genomic loci
associated with primary MN were identified. Chromosome
2q24 contains the gene encoding M-type PLA2R (PLA2R1;
SNP rs4664308), previously shown to be the target of anautoimmune response. Furthermore, chromosome 6p21
contains the gene encoding human leukocyte antigen (HLA)
complex class II HLA-DQ alpha chain 1 (HLA-DQA1; SNP
rs2187668), which was found to have a strong correlation
with MN as well. The association with HLA-DQA1 is signifi-
cant in all three populations from the French, Dutch, and
British groups. The odds ratio for idiopathic MN with ho-
mozygosity for both risk alleles is 78.5. Interactions be-
tween a trigger (genetic variants of immune-system
proteins), a bullet (PLA2R autoantibodies), and a target
(glomerular antigen) is proposed. However, the causality
remains unknown.47
In a Spanish cohort, the HLA-DQA1 and PLA2R1 poly-
morphisms were reported to predict idiopathic MN response
to immunosuppressant and disease progression.48 In a Chi-
nese cohort, among individuals who carried risk alleles for
both genes, 73% had anti-PLA2R antibodies and 75%
expressed PLA2R in glomeruli. Individuals carrying risk al-
leles are predisposed to the generation of circulating anti-
PLA2R autoantibodies, which may contribute to the devel-
opment of idiopathic MN.49 Polymorphism in other non-HLA
alleles, such as tumor necrosis factor (TNF) alpha alleles
G308A, TNFA2, and TNFd2, are associated with the devel-
opment of MN.50,51 In a Taiwanese population, poly-
morphism in NPHS1, PAI1, IL-6, STAT4, and TLR9 genes is
associated with susceptibility to the development and
progression of MN.52e57
The complement system plays a major role in the
pathogenesis of podocyte injury and proteinuria. Sub-
epithelial immune deposits initiate the complement system
activation leading to activation of C3 component, conver-
sion of C5, and subsequent formation of the C5b-9 complex
in podocyte membranes.58e63 The attack on C5b-9 complex
leads to intracellular production of reactive oxygen spe-
cies64e66 and proteases,67 endoplasmic reticulum stress,
and cytoskeletal changes.68e70 These reaction-induced cell
apoptosis,71 detachment of the cells from glomerular
basement membrane,72 degradation of glomerular base-
ment membrane, and dislocation of slit diaphragm protein
result in proteinuria and renal failure.
Early studies in Heymann nephritis showed the presence
of C3 and C5b-9 that colocalized with the immune deposits.
In a small-sized study, C3 deposits were first detected in half
of the patients with primary MN.73 Currently, C3c deposition
(a short-lived breakdown product of C3) is found in almost all
cases of MN.74 Besides, the level of C3d, a stable breakdown
product of C3, is increased in approximately 70% of patients
Figure 2 Membranous nephropathy seen under an electron
microscope. An electron microscopy image shows electron-
dense deposits in the subepithelial space (arrows). Courtesy
Wei-Chou Lin, MD, National Taiwan University Hospital, Taipei,
Taiwan.
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deposition of C4d in 100% of MN.76
The opinion about which specific complement pathway
dominates in MN is still inconclusive. IgG4 is the predomi-
nantly deposited Ig in MN.73 This finding argues against a
predominant role for the classical pathway of complement
activation, because IgG4 does not activate the classical
pathway. C1q is generated during activation of the classical
pathway but some studies do not report deposition of C1q
in primary MN.77 The presence of C4 in most cases of pri-
mary MN76,78 challenges the role for the alternative
pathway, which does not generate C4. The mannan-binding
lectin (MBL) pathway may be involved in MN.74 Based on
these Ig-related findings, a hypothesis that MBL directly
binds to hypogalactosylated IgG molecules and thereby
activates the lectin complement pathway has been pro-
posed.79 This finding may explain the presence of glomer-
ular C4 in primary MN. Segawa et al74 suggested that both
the alternative and lectin pathways were involved in the
complement activation in patients with global MN.
Different complement pathways may cooperate. Previous
studies suggested that IgG1 is the major subclass in early
stage deposits, whereas IgG4 is predominant in later
stages.80 Thus, it is proposed that IgG1 may initially acti-
vate the classic pathway in the early stage with activation
of the lectin or alternative pathways in later stages. How-
ever, further studies are needed to clarify the interplay of
different complement systems.Diagnosis of MN
The diagnosis of MN can only be made by renal biopsy.
Pathologic sine qua non of MN is the presence of sub-
epithelial immune-complex deposit, which was best
demonstrated by electron microscopy (Fig. 2).81 Churg and
Ehrenreich82 have described four ultrastructural stages of
MN: Stage I is characterized by the presence of scattered or
more regularly distributed small immune-complex-type
electron-dense deposits in the subepithelial zone. Stage II
is characterized by projections of basement membrane
material around the subepithelial deposits. In Stage III, the
new basement membrane material surrounds the deposits.
Stage IV is characterized by the loss of electron density of
the deposits, which often results in irregular electron-
lucent zones within an irregularly thickened basement
membrane (Fig. 3). The characteristic immunofluorescence
picture is diffuse global granular capillary wall staining for
immunoglobulin and complement.81 IgG is the most
frequent and usually the most intense. C3 staining is also
frequently presented.83 Under light microscopy, the char-
acteristic histological abnormality of MN is diffuse global
capillary wall thickening in the absence of significant
glomerular hypercellularity (Fig. 4).83
To diagnose idiopathic MN, secondary MN should be
excluded first. It is worth mentioning that secondary MN is
more common in children (75%) than adults (25%). Auto-
immune diseases (systemic lupus erythematosus, rheuma-
toid arthritis, etc.), infections (hepatitis B and hepatitis C),
malignancies (lung cancer, prostate cancer, and hemato-
logical malignancies), and medications were reported to be
the cause of secondary MN.84The identification of circulating autoantibodies against
the M-type PLA2R (anti-PLA2R) has been a major discovery
as mentioned earlier. Anti-PLA2R antibodies were found in
70% of patients with idiopathic MN, and were minimal in
secondary etiologies.38 However, more studies are needed
to understand whether the anti-PLA2R antibody is usually
present in general populations with idiopathic MN. Besides,
the accuracy of the test to identify idiopathic MN awaits
well-designed prospective studies.41
The distinction between primary and secondary MN can
be suggested by IgG subclasses. IgG4-rich deposits, some-
times including IgG1, especially for very early disease,
characterize primary MN.73,80 By contrast, IgG1, IgG2, and
IgG3 were mostly found in secondary MN.85,86 In addition,
the presence of a full-house pattern, IgG, IgM, IgA, C3, and
C1q, is very specific for secondary MN.87
Clinical features and natural history of MN
Proteinuria is the typical presentation of MN, and nephrotic
syndrome occurs in 70e80% of patients.88,89 Most patients
have normal or slightly decreased renal function upon
diagnosis. If progressive renal insufficiency develops, it is
usually relatively indolent. An abrupt change in renal
function indicates the necessity for prompt investigation of
a superimposed condition, such as a crescentic glomerulo-
nephritis, bilateral renal vein thrombosis, and drug
toxicity.83
A multicenter study from the Spanish Group for the
Study of Glomerular Disease (GLOSEN) examined the course
of nephrotic idiopathic membranous nephropathy patients
(n Z 328): angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker (ACEI/ARB) treatment was
started in 219 patients (66.7%). A total of 104 patients
Figure 3 Four pathological stages of membranous nephropathy. Stage I is characterized by the presence of immune-complex-
type electron-dense deposits in the subepithelial zone between the basement membrane and the podocyte. Stage II is charac-
terized by projections of basement membrane material around the subepithelial deposits. In Stage III, the new basement mem-
brane material surrounds the deposits. Stage IV is characterized by the loss of electron density of the deposits, which results in
irregular electron-lucent zones. IC Z immune complex.
106 W.L. Lai et al.(31.7%) developed spontaneous remission. Fifty percent of
patients with spontaneous remission developed complete
remission, and the time to achieve partial and complete
remission was 14.7 months and 38.5 months, respectively.Figure 4 Membranous nephropathy under a light microscope
(periodic acideSchiff stain). A light microscopy image reveals
diffuse thickening of glomerular basement membrane (ar-
rows). Courtesy of Wei-Chou Lin, MD, National Taiwan Univer-
sity Hospital, Taipei, Taiwan.Spontaneous remission was associated with excellent long-
term outcome; by contrast, failure to achieve spontaneous
remission was associated with increased risk of dialysis
(18.7%) and death (10.7%).90 In the GLOSEN study, baseline
serum creatinine level, the amount of baseline proteinuria,
treatment with ACEIs/ARBs, and a spontaneous proteinuria
decrease > 50% of the baseline value during the 1st year of
follow-up emerged as significant independent predictor
factors for spontaneous remission.90 The natural history
and the rate of spontaneous remission in Asian countries
still await large-scale studies. Besides, high levels of anti-
PLA2R were associated with a striking increase in the risk of
progression.91
Prediction of prognosis
Traditionally, the Toronto Risk Score is the most commonly
used tool to predict the prognosis in idiopathic MN. The risk
score is calculated based on time-average proteinuria
(highest sustained 6-month period of proteinuria), creati-
nine clearance (CCr) at diagnosis, and the slope of CCr over
6 months.92 The Toronto Risk Score could identify patients
at risk of progression with 85e90% accuracy.92 However,
prolonged observation is necessary for calculation of Tor-
onto Risk Score, and treatment may be delayed. As a result,
several markers were used to predict the prognosis of
idiopathic MN.
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microglobulin was used to predict the prognosis of
MN.93,94 The sensitivity and specificity of urinary excretion
of b2-microglobulin in predicting renal failure were 88% and
91%, respectively, at the cutoff point of 0.5 mg/min. The
sensitivity and specificity of urinary a1-microglobulin were
84% and 94%, respectively, in the same study, with the
threshold level at 40 mg/min.93 When comparing the prog-
nostic accuracies of Toronto Risk Score with those of uri-
nary excretion of b2-microglobulin or a1-microglobulin, no
significant difference was noted.95
A prospective multicenter study revealed that the anti-
PLA2R antibody possessed prognostic values. The patients
who achieved remission of proteinuria after 12 months had
lower anti-PLA2R antibody at the time of study inclusion,
and the anti-PLA2R antibody level is an independent risk
predictor for remission of proteinuria.96
Treatment of idiopathic MN
All patients with MN should receive excellent supportive
care, including treatment with ACEI/ARB, lipid-lowering
agents, and adequate control of blood pressure.83,97 Ac-
cording to the newest “Kidney Disease: Improving Global
Outcomes” Guideline, treatment with immunosuppressive
agents should be started only in patients with nephrotic
syndrome when (1) urinary protein excretion persistently
exceeds 4 g/d and remains at > 50% of the baseline value
during an observation period of at least 6 months; (2) se-
vere, disabling, or life-threatening symptoms related to the
nephrotic syndrome is present; (3) the creatinine level in-
creases by  30% within 6e12 months from the time of
diagnosis. For patients with serum creatinine level >
3.5 mg/dL [or estimated glomerular filtration rate
(eGFR) < 30 mL/min] and reduced kidney size (< 8 cm in
length on ultrasound), or concomitant severe or potentially
life-threatening infections, immunosuppressive therapy is
not suggested.84
Immunosuppressive agents: Steroid
The efficacy of corticosteroid monotherapy is still being
debated. Three randomized control trials in Western
countries have shown that oral steroid monotherapy is not
superior to symptomatic therapy alone in idiopathic MN.84
However, in a Japanese study, steroid monotherapy (oral
prednisolone 40e60 mg/d, then tapered over  4 weeks)
was associated with significantly better renal survival when
compared with supportive therapy.98 In our experience,
steroid use (prednisolone 0.5e1 mg/kg/d) also achieved
remission within 1 year in approximately 60e70% of
patients.
Immunosuppressive agents: Alkylating agents with
steroid
Ponticelli et al99e101 used a 6-month regimen consisting of
daily oral chlorambucil (0.2 mg/kg) or cyclophosphamide
(2e2.5 mg/kg), alternating monthly with corticosteroids
(1 g/d intravenous methylprednisolone for 3 days, and
followed by oral prednisolone 0.4e0.5 mg/kg/d), known asthe “Ponticelli protocol”, to treat the patients with idio-
pathic MN. For patients with nephrotic-range proteinuria
and normal/near normal renal function, alternating
monthly cycles of corticosteroids and an alkylating agent
were found to be more effective than supportive therapy to
achieve remissions of proteinuria and renal function pres-
ervation. Despite the favorable results with alkylating
agents, physicians are reluctant to prescribe them due to
their short-term and potential long-term adverse effects,
including myelosuppression, infection, hemorrhagic
cystitis, infertility, and increased risk of malignancy.97
Therefore, the risk and benefit for prescription should be
individualized.84 In a recent study analyzing the treatment
policy of idiopathic MN, immunosuppressive therapies were
prescribed only if deterioration of renal function, persis-
tent hypoalbuminemia, or complications of the nephrotic
syndrome such as infection and thrombosis occurred.102
This strategy prevented the use of potentially harmful
immunosuppressive drugs in half of the patients, but long-
term outcomes were still favorable.
Immunosuppressive agents: Calcineurin inhibitors
Calcineurin inhibitors (CNIs) are an effective alternative for
induction, with a remission rate of 80%. Cyclosporine
(3.5 mg/kg/d, levels of 125e200 mcg/L for 6e12 months,
then tapered to the lowest possible maintenance dose) and
tacrolimus (0.05 mg/kg/d, levels of 7e9 mcg/L for 6e12
months, then tapered) were used in clinical trials.103e106
CNIs show favorable responses in patients who have been
unresponsive to other immunosuppressants, including
alkylating agents.103,104,107,108 The antiproteinuric effect of
CNIs is typically evident early. However, if even a trivial
decrease in proteinuria was not noted by 3 months, it is
unlikely that a significant response will occur later.97 Be-
sides, relapse is a well-recognized problem, occurring in
13e50% of patients within 1 year of drug withdrawal.106
Immunosuppressive agents in patients with
deteriorating renal function
Alternating cycles of prednisolone and chlorambucil treat-
ment may be beneficial for patients with idiopathic MN and
deteriorating renal function. A randomized controlled trial
showed that 6 months of alternating cycles of prednisolone
and chlorambucil had the best outcome, and there were no
differences between the cyclosporine and supportive treat-
ment groups.109 Despite a seemingly better renal outcome,
hematological or metabolic adverse events were more com-
mon in the prednisolone and chlorambucil groups.109
Other immunosuppressive agents and novel agents
Among the newly explored therapeutic agents for idio-
pathic MN, rituximab has emerged as the most likely
candidate, although it is yet to be tested in randomized
controlled trials and there is a lack of longitudinal data.97
Different regimens have been tried for idiopathic MN;
regardless of the regimen administered, proteinuria tends
to decline slowly and remissions may occur up to 2 years
after treatment.110
108 W.L. Lai et al.Mycophenolate mofetil was also evaluated as initial
therapy in idiopathic MN.111e113 Although a regimen of
mycophenolate mofetil plus steroid might have a compa-
rable efficacy to cyclical alkylating agents and steroid, high
frequency of relapses with mycophenolate mofetil sub-
stantially reduces interest in its application.84,111
Adrenocorticotropic hormone (ACTH) was used to treat
the patients with idiopathic MN.114 The actual mechanism
by which ACTH exerts its antiproteinuric effects is currently
unknown.97 Possible mechanisms are steroid-related anti-
inflammatory actions and direct interactions between
melanocortin receptors and ACTH, which lead to immuno-
modulation and anti-inflammatory effects.114 In this study,
among the patients who received ACTH (40 U or 80 U twice
per week), 10% achieved complete remission and 50% pa-
tients achieved partial remission by 1 year. A cumulative
dose of at least 80 IU twice weekly for 3e6 months was
necessary for response, and the drug was well tolerated.114
Pentoxifylline, a phosphodiesterase inhibitor, may be
used in treatment of MN because it has anti-inflammatory
and protective effects and can decrease proteinuria in
patients with chronic kidney disease.115e117 In a small-scale
study, add-on pentoxifylline decreased urinary protein
excretion in nondiabetic MN patients.118 Leflunomide is an
inhibitor of dihydroorotate dehydrogenase, which is the key
enzyme in pyrimidine synthesis. It has antiproliferative and
anti-inflammatory effects, and is used to treat patients
with rheumatoid arthritis.119 In a retrospective study
including 32 patients, combination treatment with leflu-
nomide and steroid achieved a favorable result with 31.3%
complete remission and 40.6% partial remission. The me-
dian time to remission was 8 months; younger age was
associated with increased remission rate. Leflunomide was
well tolerated by the majority of the patients. However, a
21.3% relapse of nephrotic syndrome was noted after
cessation of leflunomide.120
Herbal medicine Astragalus membranaceus was associ-
ated with remission of proteinuria in patients with idio-
pathic MN.121,122 Recently, an open-label, randomized
controlled trial had demonstrated the efficacy of tradi-
tional Chinese medicine (Shenqi particle) for patients with
idiopathic MN.123 Shenqi particle consists of 13 herbs,
including A. membranaceus. When comparing Shenqi par-
ticle treatment with traditional immunosuppressive ther-
apy using cyclophosphamide and prednisone, the remission
rate was found to be similar between groups (73% vs. 78%).
The patients who received Shenqi particle had greater
improvement of eGFR at 48 weeks.Conclusion
MN is a major cause of nephrotic syndrome in adults. The
pathogenesis of MN involves the formation of subepithelial
immune complex, and current evidence points out that the
anti-PLA2R antibody is strongly associated with primary MN,
and proteinuria is caused by complement-mediated pro-
cess. Currently, diagnosis of MN still depends on pathology,
but the discovery of anti-PLA2R may provide a useful tool
for diagnosis and prediction of outcome of MN. The patients
with spontaneous remission have excellent outcomes.
Immunosuppressive agents should be administered topatients with persistent proteinuria, deteriorating renal
function, or severe complications. Various studies suggest
that the combination of steroid and alkylating agents is the
most effective evidence-based therapy. However, the
clinical features and treatment response vary among
different races, and there is a need to conduct more trials
to validate the efficacy of newer agents.Acknowledgments
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